m. tuberculosis

Pyrazinamide (Pyrazinecarboxamide), an antimycobacterial, is utilized therapeutically as an antitubercular agent, which is a synthetic pyrazinoic acid amide derivative.

GSK572A is a novel and potent potent inhibitor of EchA6, which can be used to treat tuberculosis.

GSK2556286 (GSK286) is an orally active inhibitor of Mycobacterium tuberculosis (M. tuberculosis), effective against multidrug-resistant (MDR), extensively drug-resistant (XDR), and drug-sensitive (DS) strains. It inhibits the growth of human macrophages with an IC50 value of 0.07 μM.

Sodium 4-aminosalicylate dihydrate (4-Amino-salicylic acid sodium salt) is the sodium salt form of aminosalicylic acid, an analog of para-aminobenzoic acid (PABA) with antitubercular activity. Sodium 4-aminosalicylate dihydrate exerts its bacteriostatic activity against Mycobacterium tuberculosis by competing with PABA for enzymes involved in folate synthesis, thereby suppressing growth and reproduction of M. tuberculosis, eventually leading to cell death.

Lansoprazole sulfide (AG-177) is an active metabolite of Lansoprazole with similar activity.Lansoprazole is a proton pump inhibitor and antitubercular agent with an IC50= 0.59 µM against Mycobacterium tuberculosis.

sCNH240 (2-Fluoro-N-[3-(3-thienyl)-5-isoxazolyl]benzenesulfonamide) is a potential and selective Rv1625c Cya activator with good cell permeability and oral activity, IC90=1.24 μM in cholesterol-supplemented 7H12 medium against Mycobacterium tuberculosis (Mtb) H37Rv strain, and inhibition of CYP2C19, CYP2C9 and hERG channels.

AX20017, a small-molecule protein kinase G (PknG) inhibitor (IC50: 0.39 μM), functions by inhibiting the proliferation of M. tuberculosis.

C-215 is a novel inhibitor of mycobacterial membrane protein large 3 (MmpL3).

BM635 is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

BM635 hydrochloride is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

BM635 mesylate is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

CRS400393 is an effective anti-mycobacterial drug , with MIC of 0.03, 2, and ≤ 0.12 µg mL against M. abs., M. avium, M. intracellulare, and M. tuberculosis, respectively.

Norverapamil hydrochloride (D591 hydrochloride) ((±)-Norverapamil hydrochloride) is an N-demethylated metabolite of Verapamil and it is an L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.

WAY-299801 is an antibacterial compound that demonstrates significant antimycobacterial activity against various Mycobacterium strains and clinically isolated M. tuberculosis in vitro.

Pks13-IN-1 (Compound 44) is an orally active inhibitor of Mycobacterium tuberculosis polyketide synthase 13 (Pks13). It inhibits the M. tuberculosis H37Rv strain with a minimum inhibitory concentration (MIC) of 0.07 μM. In mouse models, Pks13-IN-1 demonstrates antibacterial activity.

SMARt751 targets the transcriptional regulator VirS, inhibiting its ability to bind DNA, which in turn enhances the expression of the mymA operon and activates Ethionamide. This activation increases the antimicrobial efficacy of Ethionamide against Mycobacterium tuberculosis, and overcomes its resistance. Furthermore, SMARt751 augments Ethionamide's antibacterial activity in mouse models and reduces its effective dose. Additionally, SMARt751 can permeate the blood-brain barrier.

JNJ-2901 is an inhibitor of M. tuberculosis cytochrome bc1:aa3. It effectively reduces bacterial load in acute and chronic mouse infection models of M. tuberculosis H37Rv-ΔcydAB. JNJ-2901 is useful for tuberculosis (TB) research.

Mtb-IN-11 (Compound 1e) is an inhibitor of Mycobacterium tuberculosis salicylate synthase (MbtI) with an IC50 of 11.2 μM. It exhibits strong in vitro antitubercular activity, with an MIC99 of 32 μM against Mycobacterium bovis BCG. Mtb-IN-11 is applicable for tuberculosis research.

Mycobacterium Tuberculosis-IN-7 (Compound 4c) inhibits M. tuberculosis H37Ra with an MIC of 5.34 μg/mL and exhibits mild cytotoxicity against cancer cells Vero, A549, and HepG2 (IC50 > 50 μM).

Mitonafide (NSC-300288) suppresses the activity of M. tuberculosis NAD+ dependent DNA ligase A. Mitonafide is a DNA intercalating agent.

DprE1-IN-377790 is a novel DprE1 inhibitor, killing M. tuberculosis.

Q-203 Ditosylate, also known as Q-203, is a mycobacterium tuberculosis protein potentially for the treatment of tuberculosis. The optimized IPA compound Q203 inhibited the growth of MDR and XDR M. tuberculosis clinical isolates in culture broth medium in

A039 is a highly active bactericidal agent against M. tuberculosis.

Beauvericin A is a cyclodepsipeptide and derivative of beauvericin originally isolated fromB. bassianathat has diverse biological activities.1,2,3It is active againstM. tuberculosis(MIC = 25 μg/ml) andP. falciparum(IC50= 12 μg/ml).2Beauvericin A is toxic to brine shrimp (LD100= 32 μg/ml).3 1.Gupta, S., Montillor, C., and Hwang, Y.-S.Isolation of Novel Beauvericin Analogues from the Fungus Beauveria bassianaJ. Nat. Prod.58(5)733-738(1995) 2.Nilanonta, C., Isaka, M., Kittakoop, P., et al.Antimycobacterial and antiplasmodial cyclodepsipeptides from the insect pathogenic fungus Paecilomyces tenuipes BCC 1614Planta Med.66(8)756-758(2000) 3.Shi, S., Li, Y., Ming, Y., et al.Biological activity and chemical composition of the endophytic fungus Fusarium sp. TP-G1 obtained from the root of Dendrobium officinale Kimura et MigoRec. Nat. Prod.12(6)549-556(2018)